- Home
- ZTR vs MREO Comparison
ZTR vs MREO Comparison
Compare ZTR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZTR | MREO |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | Australia | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.2M | 324.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZTR | MREO |
|---|---|---|
| Price | $6.33 | $0.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 219.4K | ★ 38.5M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.50 | $0.20 |
| 52 Week High | $6.60 | $3.26 |
Technical Indicators
Market Signals| Indicator | ZTR | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 33.01 |
| Support Level | $6.23 | $0.48 |
| Resistance Level | $6.36 | $0.78 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 89.69 | 41.18 |
Price Performance
Historical ComparisonAbout ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).